Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	D17-D29
Journal	European Journal of Endocrinology
Volume	182
Issue number	6
DOIs	https://doi.org/10.1530/EJE-19-0998
Publication status	Published - 2020

Research programs

@article{044ab9829e9a4ebda68b1bbee55017e8,

title = "Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly",

author = "\{van der Lely\}, \{AJ (Aart-Jan)\} and E Kuhn and Ammar Muhammad and Eva Coopmans and S.J.C.M.M. Neggers and P Chanson",

year = "2020",

doi = "10.1530/EJE-19-0998",

language = "Undefined/Unknown",

volume = "182",

pages = "D17--D29",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly

AU - van der Lely, AJ (Aart-Jan)

AU - Kuhn, E

AU - Muhammad, Ammar

AU - Coopmans, Eva

AU - Neggers, S.J.C.M.M.

AU - Chanson, P

PY - 2020

Y1 - 2020

U2 - 10.1530/EJE-19-0998

DO - 10.1530/EJE-19-0998

M3 - Article

C2 - 32234975

SN - 0804-4643

VL - 182

SP - D17-D29

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 6

ER -